相似文献
1
How a single patient influenced HIV research--15-year follow-up.
N Engl J Med. 2014 Feb 13;370(7):682-3. doi: 10.1056/NEJMc1308413.
2
Close association of CD8+/CD38 bright with HIV-1 replication and complex relationship with CD4+ T-cell count.
Cytometry B Clin Cytom. 2009 Jul;76(4):249-60. doi: 10.1002/cyto.b.20467.
3
Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
AIDS. 2005 Jan 3;19(1):25-33. doi: 10.1097/00002030-200501030-00003.
4
HLA B*5701 status, disease progression, and response to antiretroviral therapy.
AIDS. 2013 Oct 23;27(16):2587-92. doi: 10.1097/01.aids.0000432613.95455.71.
5
Analysis of the CD8 T cell anti-HIV activity in heterologous cell co-cultures reveals the benefit of multiple HLA class I matches.
Immunogenetics. 2018 Feb;70(2):99-113. doi: 10.1007/s00251-017-1021-7. Epub 2017 Jul 22.
6
A case report of HIV-1 superinfection in an HIV controller leading to loss of viremia control: a retrospective of 10 years of follow-up.
BMC Infect Dis. 2019 Jul 5;19(1):588. doi: 10.1186/s12879-019-4229-3.
7
Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART).
PLoS One. 2015 Aug 4;10(8):e0134158. doi: 10.1371/journal.pone.0134158. eCollection 2015.
8
Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.
J Virol. 2018 Sep 12;92(19). doi: 10.1128/JVI.00811-18. Print 2018 Oct 1.
9
[Influence of HLA-A, B loci carrying Bw4 motif on HIV CD4 T cell count and viral load].
Zhonghua Yi Xue Za Zhi. 2010 Aug 24;90(32):2242-5.
10
Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression.
Scand J Infect Dis. 2013 May;45(5):368-77. doi: 10.3109/00365548.2012.744465. Epub 2012 Nov 28.
引用本文的文献
1
CD8T-cell response to mutated HLA-B*35-restricted Gag HY9 and HA9 epitopes from HIV-1 variants from Medellin, Colombia.
Heliyon. 2024 Jun 15;10(12):e33143. doi: 10.1016/j.heliyon.2024.e33143. eCollection 2024 Jun 30.
2
CCR5 as a Coreceptor for Human Immunodeficiency Virus and Simian Immunodeficiency Viruses: A Prototypic Love-Hate Affair.
Front Immunol. 2022 Jan 27;13:835994. doi: 10.3389/fimmu.2022.835994. eCollection 2022.
3
Engineering T-Cell Resistance to HIV-1 Infection via Knock-In of Peptides from the Heptad Repeat 2 Domain of gp41.
mBio. 2022 Feb 22;13(1):e0358921. doi: 10.1128/mbio.03589-21. Epub 2022 Jan 25.
4
Altered HIV-1 mRNA Splicing Due to Drug-Resistance-Associated Mutations in Exon 2/2b.
Int J Mol Sci. 2021 Dec 23;23(1):156. doi: 10.3390/ijms23010156.
5
How elite controllers and posttreatment controllers inform our search for an HIV-1 cure.
J Clin Invest. 2021 Jun 1;131(11). doi: 10.1172/JCI149414.
6
Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques.
Front Immunol. 2020 Dec 11;11:579158. doi: 10.3389/fimmu.2020.579158. eCollection 2020.
7
The current understanding of overlap between characteristics of HIV-associated neurocognitive disorders and Alzheimer's disease.
J Neurovirol. 2019 Oct;25(5):661-672. doi: 10.1007/s13365-018-0702-9. Epub 2019 Jan 22.
8
HLA-B*14:02-Restricted Env-Specific CD8 T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection.
J Virol. 2017 Oct 27;91(22). doi: 10.1128/JVI.00544-17. Print 2017 Nov 15.
9
HIV-1 selectively targets gut-homing CCR6+CD4+ T cells via mTOR-dependent mechanisms.
JCI Insight. 2017 Aug 3;2(15). doi: 10.1172/jci.insight.93230.
10
Engineering cord blood to improve engraftment after cord blood transplant.
Stem Cell Investig. 2017 May 25;4:41. doi: 10.21037/sci.2017.05.01. eCollection 2017.
本文引用的文献
1
Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection.
AIDS. 2010 Jun 19;24(10):1598-601. doi: 10.1097/qad.0b013e32833b61ba.
2
The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse).
J Acquir Immune Defic Syndr. 2006 Jun;42(2):192-202. doi: 10.1097/01.qai.0000219779.50668.e6.
3
A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study.
AIDS. 2003 Jan 3;17(1):43-51. doi: 10.1097/00002030-200301030-00007.
4
Immune control of HIV-1 after early treatment of acute infection.
Nature. 2000 Sep 28;407(6803):523-6. doi: 10.1038/35035103.
5
Control of HIV despite the discontinuation of antiretroviral therapy.
N Engl J Med. 1999 May 27;340(21):1683-4. doi: 10.1056/NEJM199905273402114.
Zotero 插件